menu
    • menu
    [{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diltiazem Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Hydralazine Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eugia Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Eugia Pharma

    Menu

    Eugia Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Steriles Receives FDA Approval for New Injectables Facility

                            Details : Lidocaine is a local anesthetic that's used to numb areas of the body before medical procedures, treat pain, and treat certain heart conditions.

                            Brand Name : Lidocaine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2024

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval For Plerixafor Injection

                            Details : Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.

                            Brand Name : Mozobil-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 25, 2023

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diltiazem Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL ...

                            Details : Diltiazem hydrochloride inhibits the inflow of calcium ions into the cardiac muscle during depolarization. Reduced intracellular calcium concentrations increase smooth muscle relaxation, resulting in arterial vasodilation and decreased blood pressure.

                            Brand Name : Diltiazem Hydrochloride-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2023

                            Lead Product(s) : Diltiazem Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Lenalidomide Capsules

                            Details : Lenalidomide (revlimid's-generic) activates NK cells, which leads to heightened immune surveillance the ability of the immune system to both identify and eliminate tumor cells. Lenalidomide has tumoricidal effects on multiple myeloma.

                            Brand Name : Revlimid-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2023

                            Lead Product(s) : Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydralazine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Hydralazine Hydrochloride Injection USP, 20 mg/mL Single-Dose Vials

                            Details : Hydralazine is a vasodilator which alters cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.

                            Brand Name : Hydralazine Hydrochloride-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : Hydralazine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Voriconazole for Injection, 200 mg/Vial Single-Dose Vial

                            Details : Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.

                            Brand Name : Vfend-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Azacitidine for Injection, 100 mg Single-Dose Vial

                            Details : Azacitidine is a pyrimidine nucleoside analog of cytidine. It is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.

                            Brand Name : Vidaza-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth